Proton Pump Inhibitors (PPIs) have been linked to an increased risk of inflammatory bowel disease (IBD), although this association has not been clearly established in prior research.
A systematic review and meta-analysis that included eight studies found a significantly higher risk of IBD in patients using PPIs, especially among Europeans, with varying odds ratios for different IBD types.
The findings suggest a noteworthy association between PPI usage and IBD risk, emphasizing the need for further research to confirm these links across different populations.